Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study. [PDF]
PLoS ONE, 2023 This paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza, an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients.
Rafael Venegas-Rodríguez +12 more
doaj +5 more sources
Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis Patients [PDF]
BiomedicinesJusvinza is an immunomodulatory drug composed of an altered peptide ligand (APL) designed from a novel CD4+ T cell epitope of human heat shock protein 60 (HSP60), an autoantigen involved in the pathogenesis of rheumatoid arthritis (RA).
Mabel Hernández-Cedeño +10 more
doaj +7 more sources
Características clínicas, radiológicas y laboratoriales de pacientes con COVID-19 tratados con Jusvinza [PDF]
Medimay, 2022 Introducción: El tratamiento con anticuerpos monoclonales en la infección por SARS-CoV-2 es controversial, algunos protocolos lo recomiendan para pacientes con enfermedad grave o en estado crítico.
Yanet Damarys Acosta Perdomo +3 more
doaj +6 more sources
Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 [PDF]
MedisurFoundation: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of
Sandra Caridad Laurencio Vallina +4 more
doaj +3 more sources
Diabetes, hiperglucemia y evolución de pacientes con la COVID-19 [PDF]
Revista Cubana de Medicina Militar, 2021 Introducción: La diabetes mellitus e hiperglucemia, en pacientes con la COVID-19, predisponen a mayor gravedad de la enfermedad y peores resultados a corto plazo.
Rubén González Tabares +4 more
doaj +4 more sources
The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19 [PDF]
Revista Cubana de Medicina Militar, 2021 Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptoms of hyperinflammation.
Rafael Venegas Rodríguez +13 more
openaire +3 more sources
Revista Cubana de Medicina Militar, 2021 Introducción: La infección con el SARS-CoV-2 induce un estado protrombótico en los pacientes, atribuible a la combinación de la respuesta hiperinflamatoria y la hipoxia.
Rafael Venegas Rodríguez +13 more
doaj +3 more sources
Péptido inmumodulador CIGB-258 para el tratamiento de pacientes graves y críticos con la COVID-19 [PDF]
Revista Cubana de Medicina Militar, 2020 Introducción: El CIGB-258 es un péptido inmunomodulador con propiedades antiinflamatorias. Objetivos: Establecer la frecuencia de dosis y el tiempo de tratamiento con el péptido CIGB-258, para pacientes críticos con la COVID-19.
Rafael Venegas Rodríguez +14 more
doaj +4 more sources
Anti-Inflammatory Activity of CIGB-258 against Acute Toxicity of Carboxymethyllysine in Paralyzed Zebrafish via Enhancement of High-Density Lipoproteins Stability and Functionality. [PDF]
Int J Mol Sci, 2022 Background: Hyperinflammation is frequently associated with the chronic pain of autoimmune disease and the acute death of coronavirus disease (COVID-19) via a severe cytokine cascade.
Cho KH, Kim JE, Nam HS, Kang DJ, Na HJ.
europepmc +2 more sources
Enhancing Wound Healing and Anti-Inflammatory Effects by Combination of CIGB-258 and Apolipoprotein A-I against Carboxymethyllysine Toxicity in Zebrafish: Insights into Structural Stabilization and Antioxidant Properties [PDF]
AntioxidantsCIGB-258 is known to exert anti-inflammatory activity via structural stabilization of apolipoprotein A-I (apoA-I) and functional enhancement of high-density lipoproteins (HDL) against acute toxicity of carboxymethyllysine (CML).
Kyung-Hyun Cho +6 more
doaj +2 more sources